S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
NASDAQ:TGTX

TG Therapeutics (TGTX) Stock Forecast, Price & News

$8.36
-0.41 (-4.68%)
(As of 09/29/2023 ET)
Compare
Today's Range
$8.14
$8.89
50-Day Range
$8.36
$20.69
52-Week Range
$4.86
$35.67
Volume
5.65 million shs
Average Volume
3.82 million shs
Market Capitalization
$1.26 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.14

TG Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.57 Rating Score
Upside/​Downside
176.8% Upside
$23.14 Price Target
Short Interest
Bearish
21.52% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.46
Upright™ Environmental Score
News Sentiment
0.95mentions of TG Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
Acquiring Shares
$1.01 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.77) to $0.08 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.08 out of 5 stars

Medical Sector

599th out of 972 stocks

Pharmaceutical Preparations Industry

284th out of 451 stocks


TGTX stock logo

About TG Therapeutics (NASDAQ:TGTX) Stock

TG Therapeutics Inc is a biopharmaceutical company that develops and commercializes innovative treatments for multiple sclerosis (MS) and other autoimmune diseases. The company, founded in 2012, is headquartered in New York City and has operations in the United States and Europe. The company aims to provide new and effective therapies to patients with unmet medical needs.

TG Therapeutics has made significant achievements since its inception but has also experienced significant setbacks. The company initially rose to fame by producing the cancer drug Ukoniq which was later pulled from the market due to its ineffectiveness. The company shifted focus and received FDA approvals for a multiple sclerosis drug, Briumvi, for relapsing forms of multiple sclerosis. Additionally, the company conducts extensive clinical trials for other product candidates. These product candidates can potentially provide new treatment options for patients with B-cell malignancies and autoimmune diseases.

TG Therapeutics has a talented and experienced management team dedicated to advancing the company's mission. The current CEO and co-founder of the company is Michael S. Weiss, who has over 25 years of experience in the biopharmaceutical industry. TG Therapeutics has seen financial growth and decline over the past few years. The company has reported significant losses primarily due to removing Ukoniq from its product line and increased investment in clinical development and research activities. 

TG Therapeutics has seen significant volatility in its stock price over the past few years. In 2021, the stock price increased by over 200% due to positive clinical trial results for its product candidates. However, in 2022, the stock price experienced a sharp decline due to concerns about removing the approved drug Ukoniq from the market, delays in clinical development and increased competition. 

TG Therapeutics operates in the biopharmaceutical industry, characterized by high innovation levels and significant regulatory oversight. The industry is also subject to political and economic pressures, including changes in healthcare policy and pricing pressures from payers.

TG Therapeutics faces competition from other companies developing cancer and autoimmune disease treatments, including large pharmaceutical companies such as Roche and Novartis. However, the company's focus on developing novel therapies for unmet medical needs gives it a competitive advantage.

TG Therapeutics has several growth opportunities in its pipeline. The company is currently developing new product candidates which have the potential to provide new treatment options for patients with MS, B-cell malignancies and autoimmune diseases. Additionally, the company may pursue strategic acquisitions or partnerships to expand its product portfolio and reach new markets.

TG Therapeutics faces risks and challenges that may impact its future growth and success. These include changes in healthcare policy and pricing pressures from payers and increased competition from other companies in the market. Additionally, the company is subject to regulatory oversight and must successfully navigate the clinical development and approval process for its product candidates. Failure to do so may result in delays, increased costs, and potential setbacks for the company.

The company's financial performance is also subject to risks, such as changes in interest rates and the availability of financing. The company's debt levels may limit its ability to invest in research and development. Any significant changes in ownership or management may also disrupt operations and impact the company's growth potential.

Furthermore, the success of TG Therapeutics' product candidates is not guaranteed, and the company may need help demonstrating their safety and efficacy in clinical trials. Failure to obtain regulatory approval for these products or to effectively commercialize them may significantly impact the company's financial performance and market position.

TGTX Price History

TGTX Stock News Headlines

TG Therapeutics (NASDAQ:TGTX) Trading Down 6.3%
Biden's Digital Dollar Nightmare
On July 20th, 2023, the Federal Reserve launched FedNow, which could spark the fuse for a Digital Dollar. If a Digital Dollar happens, the government could: Monitor every transaction, keep track of your spending habits, and potentially control your individual choices… Which MAY steal your freedoms in one way or another. And if you don’t plan for this now... Your retirement savings could be at risk of being frozen, hacked, or deleted. You’ll want to act fast... Because with Biden’s long history of voting against Americans... Who knows how much longer until Biden strikes again! Get your hands on this FREE Wealth Protection Kit today and learn how you could shield your savings and investments before it’s too late!
Biden's Digital Dollar Nightmare
On July 20th, 2023, the Federal Reserve launched FedNow, which could spark the fuse for a Digital Dollar. If a Digital Dollar happens, the government could: Monitor every transaction, keep track of your spending habits, and potentially control your individual choices… Which MAY steal your freedoms in one way or another. And if you don’t plan for this now... Your retirement savings could be at risk of being frozen, hacked, or deleted. You’ll want to act fast... Because with Biden’s long history of voting against Americans... Who knows how much longer until Biden strikes again! Get your hands on this FREE Wealth Protection Kit today and learn how you could shield your savings and investments before it’s too late!
3 Very Oversold Biotech Stocks to Buy Right Now
10 Oversold Healthcare Stocks to Buy
TGTX Aug 2023 25.000 put
TGTX Aug 2023 28.000 call
See More Headlines
Receive TGTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TG Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TGTX Company Calendar

Last Earnings
8/01/2023
Today
10/01/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TGTX
Employees
244
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$23.14
High Stock Price Forecast
$41.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+176.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

Net Income
$-198,340,000.00
Net Margins
-730.34%
Pretax Margin
-730.34%

Debt

Sales & Book Value

Annual Sales
$2.79 million
Book Value
$0.40 per share

Miscellaneous

Free Float
137,088,000
Market Cap
$1.26 billion
Optionable
Optionable
Beta
2.09
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Michael S. Weiss Esq.Mr. Michael S. Weiss Esq. (Age 57)
    Chairman, CEO & Pres
    Comp: $1.97M
  • Mr. Sean A. Power CPAMr. Sean A. Power CPA (Age 41)
    CPA, CFO, Corp. Sec. & Treasurer
    Comp: $652.6k
  • Jenna Bosco
    Sr. VP of Corp. Communications
  • Mr. Adam Waldman
    Chief Commercialization Officer













TGTX Stock - Frequently Asked Questions

Should I buy or sell TG Therapeutics stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TG Therapeutics in the last year. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" TGTX shares.
View TGTX analyst ratings
or view top-rated stocks.

What is TG Therapeutics' stock price forecast for 2023?

7 brokers have issued 12-month price targets for TG Therapeutics' stock. Their TGTX share price forecasts range from $6.00 to $41.00. On average, they predict the company's stock price to reach $23.14 in the next twelve months. This suggests a possible upside of 176.8% from the stock's current price.
View analysts price targets for TGTX
or view top-rated stocks among Wall Street analysts.

How have TGTX shares performed in 2023?

TG Therapeutics' stock was trading at $11.83 at the beginning of 2023. Since then, TGTX shares have decreased by 29.3% and is now trading at $8.36.
View the best growth stocks for 2023 here
.

When is TG Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our TGTX earnings forecast
.

How were TG Therapeutics' earnings last quarter?

TG Therapeutics, Inc. (NASDAQ:TGTX) issued its quarterly earnings results on Tuesday, August, 1st. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.26) by $0.08. The biopharmaceutical company earned $16.07 million during the quarter, compared to analyst estimates of $17.39 million. TG Therapeutics had a negative trailing twelve-month return on equity of 309.58% and a negative net margin of 730.34%. The business's revenue for the quarter was up 2606.1% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.30) EPS.

What ETFs hold TG Therapeutics' stock?

ETFs with the largest weight of TG Therapeutics (NASDAQ:TGTX) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE).AdvisorShares Let Bob AI Powered Momentum ETF (LETB).

What other stocks do shareholders of TG Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TG Therapeutics investors own include Novavax (NVAX), AK Steel (AKS), Micron Technology (MU), Cara Therapeutics (CARA), Gilead Sciences (GILD), UrtheCast (UR), Verastem (VSTM), BioDelivery Sciences International (BDSI), Sorrento Therapeutics (SRNE) and Corbus Pharmaceuticals (CRBP).

What is TG Therapeutics' stock symbol?

TG Therapeutics trades on the NASDAQ under the ticker symbol "TGTX."

How do I buy shares of TG Therapeutics?

Shares of TGTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TG Therapeutics' stock price today?

One share of TGTX stock can currently be purchased for approximately $8.36.

How much money does TG Therapeutics make?

TG Therapeutics (NASDAQ:TGTX) has a market capitalization of $1.26 billion and generates $2.79 million in revenue each year. The biopharmaceutical company earns $-198,340,000.00 in net income (profit) each year or ($1.27) on an earnings per share basis.

How many employees does TG Therapeutics have?

The company employs 244 workers across the globe.

How can I contact TG Therapeutics?

TG Therapeutics' mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The official website for the company is www.tgtherapeutics.com. The biopharmaceutical company can be reached via phone at (212) 554-4484, via email at ir@tgtxinc.com, or via fax at 212-554-4531.

This page (NASDAQ:TGTX) was last updated on 10/1/2023 by MarketBeat.com Staff

My Account -